Pre-made Sutimlimab benchmark antibody ( Whole mAb, anti-C1S therapeutic antibody, Anti-EDSPD2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Sutimlimab biosimilar, Whole mAb, Anti-C1S Antibody: Anti-EDSPD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sutimlimab (INN; development code BIVV009) is a monoclonal antibody that is being investigated for cold agglutinin disease.
| Products Name (INN Index) | Pre-Made Sutimlimab biosimilar, Whole mAb, Anti-C1S Antibody: Anti-EDSPD2 therapeutic antibody |
|---|---|
| INN Name | Sutimlimab |
| Target | C1S |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Bioverativ,True North Therapeutics |
| Conditions Approved | NA |
| Conditions Active | Autoimmune haemolytic anaemia,Idiopathic thrombocytopenic purpura |
| Conditions Discontinued | Bullous pemphigoid,Renal transplant rejection |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | C1S |
| Package |
